title: Successful minimally-invasive management of a case of giant prostatic hypertrophy associated with recurrent nephrogenic adenoma of the prostate.
abstract: BACKGROUND
  Benign Prostatic Hypertrophy (BPH) is said to affect at least a third of men over 60. However, the literature contains fewer than 200 reports of prostates over 200g in mass - Giant Prostatic Hypertrophy (GPH). Nephrogenic adenomas are benign lesions of the urinary tract that are believed to represent the local proliferation of shed renal tubular cells implanting at sites of urothelial injury.
  
  
  METHODS
  We present the first case in the literature of these two rare pathologies co-existing in the same patient and the successful management and 36-month follow-up of the patient's symptoms with minimally invasive therapy, including the still-uncommon selective prostatic artery embolisation. We also briefly discuss the role of PAX2 in injured renal tissues and nephrogenic adenomas.
  
  
  CONCLUSIONS
  Symptomatic Giant Prostatic Hypertrophy (GPH) can be successfully managed with a combination of serial TURPs, 5 α-reductase inhibition and selective prostatic artery embolisation (SPAE).
authors.affiliation: Department of Urology, Kent & Canterbury Hospital, East Kent Hospitals NHS University Foundation Trust, London, UK. robertlearney@mac.com
authors.forename: Robert M
authors.initials: RM
authors.lastname: Learney
authors.forename: Sachin
authors.initials: S
authors.lastname: Malde
authors.forename: Mark
authors.initials: M
authors.lastname: Downes
authors.forename: Nitin
authors.initials: N
authors.lastname: Shrotri
mesh_terms: D000236:Adenoma / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D019060:Minimally Invasive Surgical Procedures / Q000379:methods*; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*
references.citation: Kurume Med J. 2003;50(3-4):151-3
references.pmid: 14768479
references.citation: Northwest Med. 1949 Mar;48(3):182-5
references.pmid: 18114097
references.citation: Arch Pathol Lab Med. 2010 Oct;134(10):1455-9
references.pmid: 20923300
references.citation: Nephrol Dial Transplant. 2009 Sep;24(9):2628-33
references.pmid: 19556301
references.citation: BJU Int. 2010 Aug;106(4):500-3
references.pmid: 20128777
references.citation: Adv Anat Pathol. 2006 Sep;13(5):247-55
references.pmid: 16998318
references.citation: Am J Surg Pathol. 2001 Jun;25(6):802-8
references.pmid: 11395559
references.citation: Mod Pathol. 2006 Mar;19(3):356-63
references.pmid: 16400326
references.citation: Curr Urol Rep. 2003 Apr;4(2):171-6
references.pmid: 12648437
references.citation: Zhonghua Nan Ke Xue. 2011 Feb;17(2):151-5
references.pmid: 21404714
references.citation: Hinyokika Kiyo. 1999 May;45(5):375-7
references.pmid: 10410325
references.citation: Am J Surg Pathol. 2009 Nov;33(11):1654-8
references.pmid: 19730362
references.citation: N Engl J Med. 2002 Aug 29;347(9):653-9
references.pmid: 12200552
references.citation: Urology. 2008 Feb;71(2):181-4
references.pmid: 18308078
references.citation: J Vasc Interv Radiol. 2011 Jan;22(1):11-9; quiz 20
references.pmid: 21195898
references.citation: Oncogene. 2003 Nov 6;22(50):8145-55
references.pmid: 14603255
references.citation: Hum Pathol. 1994 Apr;25(4):390-5
references.pmid: 7512941
references.citation: Bord Chir. 1952 Apr;2:95-7
references.pmid: 12987498
references.citation: BJU Int. 2000 Dec;86(9):951-9
references.pmid: 11119085